---
title: "Insider Move: Palisade Bio Director Makes Bold New Stock Bet"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292141681.md"
description: "Palisade Bio Director Robert Baltera purchased 50,000 shares worth $101,900, signaling confidence in the company. This follows FDA clearance for its IND for PALI-2108, enabling a Phase 2 trial for ulcerative colitis. Shareholders also approved increased authorized shares to enhance capital flexibility. Despite these positive developments, TipRanks' AI Analyst rates PALI as Neutral due to weak financials, cash burn, and bearish technical signals, with the stock down 11.49% year-to-date."
datetime: "2026-07-09T02:02:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292141681.md)
  - [en](https://longbridge.com/en/news/292141681.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292141681.md)
generator: "portal-rs"
---

# Insider Move: Palisade Bio Director Makes Bold New Stock Bet

Director Robert Baltera has demonstrated confidence in Palisade Bio by purchasing 50,000 shares of the company’s stock in a transaction valued at $101,900, signaling a notable insider bet on the firm’s future prospects.

Palisade Bio drew attention after the FDA cleared its IND for oral candidate PALI-2108, enabling a global Phase 2 trial in moderately to severely active ulcerative colitis, which investors view as a key clinical and valuation catalyst. At the same time, shareholder approval to boost authorized shares and expand equity plans increased the company’s financial and capital-raising flexibility, a factor analysts weigh against ongoing losses and cash burn when reassessing price targets and risk-reward.

**Spark’s Take on PALI Stock**

According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.

The score is held down primarily by very weak financial performance (minimal revenue, large losses, and continued cash burn) and bearish technical signals (below major moving averages with negative MACD). Corporate events provide some support via a development partnership and incremental funding, but potential dilution and the lack of meaningful profitability/valuation anchors limit the overall rating.

To see Spark’s full report on PALI stock,  
 click here. 

**More about Palisade Bio**

**YTD Price Performance:** -11.49%

**Average Trading Volume:** 3,898,462

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $354.1M

### Related Stocks

- [PALI.US](https://longbridge.com/en/quote/PALI.US.md)

## Related News & Research

- [FY2030 EPS Estimates for Palisade Bio Reduced by Analyst](https://longbridge.com/en/news/296061307.md)
- [Palisade Bio Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295446808.md)
- [Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2](https://longbridge.com/en/news/293653896.md)
- [Palisade Bio wins FDA IND clearance for PALI-2108 ulcerative colitis trial](https://longbridge.com/en/news/291145871.md)
- [Baidu: AI-powered business growth offset revenue decline, with strong cash flow and global expansion](https://longbridge.com/en/news/296208127.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**